SELLAS Life Sciences terminates $50M ATM sales agreement with Cantor Fitzgerald

SELLAS Life Sciences Group, Inc.

Mutual termination of Controlled Equity Offering Sales Agreement dated April 16, 2021.
ATM program allowed up to $50M in common stock sales; prior termination, 1,294,814 shares sold for ~$10.5M net.
Related prospectus supplement filed in 2021 also terminated effective immediately.
Company may explore alternative financing options going forward.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SELLAS Life Sciences Group, Inc. terminated Sales Agreement with Cantor Fitzgerald & Co. valued at up to an aggregate of $50,000,000 (effective 2024-01-02).

Action: termination
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Value: up to an aggregate of $50,000,000
Effective: 2024-01-02

Exact text from the filing

On January 2, 2024, SELLAS Life Sciences Group, Inc. (the “Company”) and Cantor Fitzgerald & Co. (the “Agent”) mutually agreed to terminate the Controlled Equity Offering SM Sales Agreement, dated April 16, 2021 (“Sales Agreement”), pursuant to which the Company could from time to time offer and sell up to an aggregate of $50,000,000 of shares of its common stock

View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-000958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.